EUVIMEDEUVIMED entdecken
Crossref

Coexistent Endometrial and Fallopian Tube Carcinoma: Molecular and Pathological Features for Risk Stratification

Kianoosh Keyhanian, C Blake Gilks, Elizabath Priya Mathew, Tanner Mack, Harman Sekhon, Bryan Lo, Peter Greenstreet, Katherine Grondin, Jessica N McAlpine, Amy Jamieson

Modern Pathology · 2026

DOI: 10.1016/j.modpat.2026.101030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026. Verfasst von Kianoosh Keyhanian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology of Laboratory Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada. Electronic address: kikeyhanian@t…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Fallopian Tube Neoplasms, Carcinoma. Die Arbeit nennt 32 Literaturangaben. Gefördert von: University of Ottawa, University of Ottawa Faculty of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with coexistent endometrial and ovarian carcinoma (CEOC) have been shown to have an excellent prognosis if their tumors meet the International Federation of Gynecology and Obstetrics (FIGO) 2023 endometrial carcinoma (EC) stage IA3 criteria. In addition, excluding the intermediate-risk and high-risk molecular subtypes (mismatch repair deficiency, p53 abnormal, and no specific molecular profile- estrogen receptor low/negative) has been recently shown to improve risk stratification in CEOC. In contrast, coexistent EC with fallopian tube (FT) involvement is considered pathological T3/FIGO stage III. Our objective was to assess whether the FIGO 2023 IA3 criteria for CEOC can identify a subset of patients with coexistent EC and FT carcinoma at low risk of recurrence and if incorporation of molecular features can aid in prognostic stratification. An institutional database search was carried out at 2 institutions to identify T3a EC with FT involvement. Cases with nodal, pelvic sidewall, vaginal, parametrial, adnexal soft tissue, or peritoneal involvement or treated with neoadjuvant therapy were excluded. A total of 71 patients were identified. Fourteen carcinomas (14/71, 19.7%) recurred; of these, 85.7% (12/14) were endometrioid FIGO grade 3 or nonendometrioid histotypes, and 85.7% (12/14) had intermediate or adverse molecular features. Eight carcinomas (8/71, 11.3%) met the FT-adapted FIGO 2023 IA3 criteria with no recurrences. Further modifying the criteria by excluding tumors with adverse molecular features while expanding the pathology criteria to include ovarian and/or bilateral adnexal involvement identified 11 of 71 patients (15.5%), none of whom experienced a recurrence. By adapting the FIGO 2023 criteria for low-risk CEOC to assess coexistent EC and FT carcinoma, we identified a subset of patients with excellent outcomes, such that treatment de-escalation could be considered. Furthermore, it may be possible to expand this category of low-risk coexistent EC and FT carcinoma, based on refined molecular/pathological features, so more patients with uterus/adnexa-confined carcinoma and indolent disease behavior can be identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsFallopian Tube NeoplasmsCarcinomaHumansFemaleMiddle AgedAgedRisk AssessmentAged, 80 and overBiomarkers, TumorPrognosisNeoplasm StagingAdult

Stichwörter der Autor:innen

coexistent endometrial and ovarian carcinomaendometrial carcinomafallopian tube carcinomamolecular classification

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology of Laboratory Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada. Electronic address: kikeyhanian@toh.ca.
  • Department of Pathology and Laboratory Science, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Pathology of Laboratory Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Ottawa Methods Centre, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Department of Pathology, Laval University, Quebec City, Quebec, Canada.
  • Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of British Columbia, Vancouver, British Columbia, Canada.

Förderung

  • University of Ottawa
  • University of Ottawa Faculty of Medicine

Zitieren

APA

Keyhanian, K., Gilks, C. B., Mathew, E. P., Mack, T., Sekhon, H., Lo, B., Greenstreet, P., Grondin, K., McAlpine, J. N., & Jamieson, A. (2026). Coexistent Endometrial and Fallopian Tube Carcinoma: Molecular and Pathological Features for Risk Stratification. Modern Pathology. https://doi.org/10.1016/j.modpat.2026.101030

Vancouver

Keyhanian K, Gilks CB, Mathew EP, Mack T, Sekhon H, Lo B, et al. Coexistent Endometrial and Fallopian Tube Carcinoma: Molecular and Pathological Features for Risk Stratification. Modern Pathology. 2026. doi:10.1016/j.modpat.2026.101030

BibTeX
@article{Keyhanian2026,
  author = {Keyhanian, Kianoosh and Gilks, C Blake and Mathew, Elizabath Priya and Mack, Tanner and Sekhon, Harman and Lo, Bryan and Greenstreet, Peter and Grondin, Katherine and McAlpine, Jessica N and Jamieson, Amy},
  title = {Coexistent Endometrial and Fallopian Tube Carcinoma: Molecular and Pathological Features for Risk Stratification},
  journal = {Modern Pathology},
  year = {2026},
  doi = {10.1016/j.modpat.2026.101030}
}
Kostenlos starten →